Semaglutide research found weight loss and fewer major health problems.
You’ll learn who was studied, the change seen, and the doubt left.
The studies found less weight and fewer major problems
Start with what happened to people. Weight fell, and some heart and kidney problems happened less often.
The main weight study found about 15% average loss over roughly 16 months [1]. That average won’t predict your loss.
SUSTAIN-6 found fewer strokes and heart attacks [2]. Another heart study also found fewer major problems [3].
The kidney study found slower loss of kidney function [6]. Another weight study compared Semaglutide with tirzepatide, a newer weight medicine [7].
Semaglutide copies a gut hormone doctors call GLP-1. The hormone helps insulin work and tells your brain you’re full.
Each number belongs to the study named beside it. Those study amounts aren’t dose advice for you.
One study can’t answer everything. Read together, the results give you and your doctor a fuller view.
Semaglutide eased hunger without making bodies burn more fuel
A meal makes your gut release a hormone doctors call GLP-1. GLP-1 signals your pancreas to put insulin into the blood as sugar rises.
Your body breaks GLP-1 down within about two minutes. A body chemical called DPP-4 does the breaking.
You won’t need that name again. The chemical’s job is what matters.
Picture the medicine as a short protein chain. Its makers changed link 8 to slow DPP-4’s breakdown of the medicine.
They added a fatty part so the drug could travel beside a protein in your blood, which keeps your kidneys from clearing the medicine from your body too quickly.
Together, the changes let one shot last close to a week. Semaglutide still does GLP-1’s job.
The drug also lowers a second hormone that makes blood sugar climb between meals. Your stomach doesn’t empty as fast, so fullness may last longer.
In mice, the drug led to less eating and different food choices [4]. Their bodies kept burning fuel at the same rate.
The medicine showed up in brain parts tied to hunger and fullness. A mouse result can’t prove exactly what happens in you.
A review confirms the point: DPP-4 breaks the drug down less easily, and a blood protein slows its exit [11]. Here’s the plain result: less hunger, not fat burned by the drug.
STEP studies found that weight returned after treatment stopped
STEP 1 followed 1,961 adults without diabetes. They had obesity or extra weight.
With Semaglutide 2.4 mg, average loss reached 14.9% at 68 weeks. Placebo users lost 2.4% [1].
STEP 2 included adults with type 2 diabetes [10]. STEP 5 found weight stayed down across two years [8].
STEP 4 changed treatment after week 20. By week 68, those staying on Semaglutide lost another 7.9% [9].
People who moved to placebo gained 6.9%. The weight effect didn’t last without the medicine.
STEP TEENS tested a 2.4 mg shot in teenagers. Their height-and-weight measure improved more than with placebo over 68 weeks [23].
A STEP 1 follow-up showed the catch. Within a year, people regained weight equal to 11.6 percent of their starting weight [17].
The group average won’t set your result. You’ll also need to plan for what may happen after stopping.
Heart, kidney, and liver harm dropped in later studies
SUSTAIN-6 followed 3,297 people with type 2 diabetes. They were already likely to have heart trouble.
Fewer Semaglutide users had a stroke, heart attack, or heart death [2]. A 95% check asks if luck might explain the difference.
The lower number of heart problems held after that check. More eye trouble appeared when blood sugar fell quickly.
That extra eye trouble also passed a 95% check against luck. A later heart study followed 17,604 adults who had heart disease plus extra weight.
They didn’t have diabetes. The Semaglutide shot cut major heart trouble by 20% [3].
The lower risk held after the same 95% check. A kidney study followed 3,533 people whose type 2 diabetes had harmed their kidneys.
Major kidney trouble fell by 24% with the weekly shot [6]. That result also held after a 95% check for luck.
In 2025, a phase 3 study was a large late test in people with fatty, swollen livers. The shot cleared swelling without worse scarring in 62.9%.
Placebo did the same in 34.3% [12]. These gains still don’t mean every person was helped.
Your own risks may be different. A doctor who knows you can put these results in their proper place.
Semaglutide vs tirzepatide favored tirzepatide for weight loss
Tirzepatide is another medicine used for weight loss. SURMOUNT-5 compared it with Semaglutide in 751 adults with obesity.
At 72 weeks, the tirzepatide group had lost 20.2% on average. The Semaglutide group had lost 13.7% [7].
The gap was clear enough that luck was an unlikely cause. Tirzepatide copies two gut hormones, while Semaglutide copies only GLP-1.
Both medicines brought large average losses in this study. Tirzepatide brought the larger one.
SURMOUNT-5 didn’t compare heart or kidney results. Other studies tested Semaglutide for those problems [3][6].
Weight isn’t the only part of your choice. We don’t rank brands.
This result can’t settle your choice by itself. You still need to compare risks and other health gains.
Long-term help came with side effects, cost, and years of care
The weight loss was large, but it wasn’t permanent. Studies found it lasted while people stayed on treatment.
A stopping study and later follow-up found regain [9][17]. Keep that result in mind when discussing years of care.
Studies of the heart and kidneys reported fewer major problems. A newer study also found help for a fatty, swollen liver.
Stomach trouble was the main reason people quit. A safety review found most cases were mild and short [5].
The review found more help than harm overall. It couldn’t settle the questions about pancreas or thyroid cancer.
Semaglutide is a GLP-1 drug, meaning it copies a gut hormone. You can open each paper on Semaglutide references.
Here’s the tradeoff: possible health gains against side effects, medicine cost, and years of treatment. Bring all three to your doctor.
The studies can’t choose for you. They give you facts for that talk.